Summary
Thermo Fisher Scientific Inc. (TMO) filed an 8-K on July 6, 2020, to announce preliminary results for the fiscal quarter ended June 27, 2020. While the 8-K itself is a brief filing, it incorporates a press release that provides key financial and operational updates. Investors should note that this filing is primarily for furnishing information rather than making new declarations, as indicated by the disclaimer that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act. The core of this announcement revolves around the company's performance during a period significantly impacted by the COVID-19 pandemic. The press release (Exhibit 99.1) likely details revenue figures, earnings, and potentially segment performance, especially highlighting areas that may have seen increased demand due to the pandemic, such as diagnostics and life sciences research. Investors should focus on any commentary regarding the pandemic's impact on demand, supply chain, and the company's outlook, as well as any strategic updates.
Key Highlights
- 1Thermo Fisher Scientific announced preliminary results for its fiscal quarter ended June 27, 2020, via an 8-K filing on July 6, 2020.
- 2The filing incorporates a press release (Exhibit 99.1) containing the detailed financial and operational update.
- 3Information furnished in this 8-K is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
- 4The report includes a cautionary statement regarding forward-looking statements, emphasizing risks and uncertainties, particularly those related to the COVID-19 pandemic.
- 5Key factors that could affect actual results are listed, including the pandemic's duration and severity, technological changes, economic conditions, and potential impacts from acquisitions.
- 6The company references its Form 10-Q for the quarter ended March 28, 2020, for a more detailed discussion of risk factors.